Key result
Human urotensin II upregulated NADPH oxidase subunits p22phox and NOX4, increased ROS levels, and enhanced proliferation and PAI-1 expression in pulmonary artery smooth muscle cells.
Why the study?
Does human urotensin II activate NADPH oxidase and promote proliferation in human pulmonary artery smooth muscle cells?
Does human urotensin II activate NADPH oxidase and promote proliferation in human pulmonary artery smooth muscle cells?
Human urotensin II promotes pulmonary artery smooth muscle cell proliferation and remodeling via NADPH oxidase activation, highlighting a potential mechanistic pathway in pulmonary hypertension.
May link urotensin II to pulmonary vascular remodeling; leaves open therapeutic targeting in pulmonary hypertension.
BACKGROUND: Human urotensin II (hU-II) is a potent vasoactive peptide possibly involved in pulmonary hypertension. Because the signaling mechanisms activated by this peptide in the pulmonary vasculature are largely unknown, we investigated the role of hU-II in the activation of NADPH oxidase and the control of redox-sensitive kinase pathways, expression of plasminogen activator inhibitor-1 (PAI-1), and proliferation in pulmonary artery smooth muscle cells (PASMCs). METHODS AND RESULTS: hU-II upregulated expression of the NADPH oxidase subunits p22phox and NOX4 and increased the levels of reactive oxygen species (ROS), which were abrogated by transfecting p22phox or NOX4 antisense vectors. p22phox and NOX4 also contributed to hU-II-induced activation of extracellular signal-regulated kinase 1/2, p38 mitogen-activated protein kinase, c-Jun N-terminal kinase, and protein kinase B (Akt). Furthermore, hU-II increased the expression of PAI-1 and enhanced PASMC proliferation in an NADPH oxidase- and kinase-dependent manner. CONCLUSIONS: hU-II is a potent activator of ROS generation by NADPH oxidase in PASMCs, leading to redox-sensitive activation of mitogen-activated protein kinases and Akt and subsequently to enhanced PAI-1 expression and increased proliferation. These findings suggest that hU-II may play a novel role in pulmonary hypertension by promoting remodeling processes via activation of NADPH oxidases.
No takes yet. Share an insight, caveat, or question.
Djordjevic et al. (2004) studied Pulmonary hypertension. Human urotensin II (hU-II) was evaluated on Activation of NADPH oxidase, ROS generation, expression of PAI-1, and proliferation in PASMCs. Human urotensin II upregulated NADPH oxidase subunits p22phox and NOX4, increased ROS levels, and enhanced proliferation and PAI-1 expression in pulmonary artery smooth muscle cells.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: